Search EN menu en EIB GROUP CLIENT PORTAL
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 100,000,000
    Countries
    Sector(s)
    Denmark : € 100,000,000
    Industry : € 100,000,000
    Signature date(s)
    26/01/2023 : € 100,000,000

    Summary sheet

    Release date
    30 November 2022
    Status
    Reference
    Signed | 26/01/2023
    20220504
    Project name
    Promoter - financial intermediary
    NOVOZYMES INNOVATIVE BIOTECHNOLOGY SOLUTIONS
    NOVOZYMES A/S
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 100 million
    EUR 287 million
    Location
    Sector(s)
    Description
    Objectives

    Novozymes's research, development and innovation (RDI) investments for the development of innovative industrial enzymes, proteins and microorganisms.

    The RDI activities will focus on the development of products and solutions that enhance product quality and process/energy efficiency in industries such as detergents, food and beverages, bioenergy, agriculture and feed and technical industries.

    Additionality and Impact

    The project's activities are in line with the priorities under Horizon Europe Pillar 2 - Global Challenges & European Industrial Competitiveness. The project is eligible under Article 309 point (c) Common interest, and qualifies under the Bank's "Innovation; Digital and Human Capital" public policy goal.


    The financing of this project supports RDI activities in the development of new products and technologies in the area of industrial enzymes and micro-organisms. The project is expected to improve (i) the productivity of the promoter's customers through the development of innovative solutions in terms of performance, quality, speed, safety, flexibility as well as (ii) the cost competitiveness of the promoter's products and technologies.


    A part of the projects activities is expected to generate positive contributions in terms of improvement of productivity, energy saving and environmental sustainability; subsequently, the project is expected to contribute to the Bank's Climate Action & Environmental Sustainability objectives (this will be assessed in detail during the project appraisal).


    The promoter's investments address the market failures and gaps associated with (i) imperfect competition and incomplete markets for innovative sustainable technologies, and those addressed by (ii) projects with positive knowledge, environmental and safety externalities generation.


    The EIB support to this operation is expected to provide tangible value-added benefit, positively contributing to the promoter's RDI investments by lowering the associated cost of financing and offering more flexible terms compared to the commercial banks.


    Environmental aspects
    Procurement

    The project includes RDI activities that are not specifically mentioned under the EIA Directive and that will be carried out in existing facilities without changing their already authorised scope. The project will therefore not require an environmental impact assessment (EIA) under the directive 2014/52/EU amending directive 2011/92/EU.

    The promoter is a private company not operating in the Utilities sector and not having a status of a contracting entity. Thus it is not covered by EU Directives on procurement.

    Comments

    Enzyme-assisted products and processes enjoy increasing demand, because they typically replace more environmentally intrusive conventional chemical or more energy intensive processes. Henceforth, following the net-positive effect of enzymatic processes on the environment and their very broad range of applications, this programme will also have a positive contribution on climate action and environmental sustainability.

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - NOVOZYMES INNOVATIVE BIOTECHNOLOGY SOLUTIONS
    Publication Date
    7 Feb 2023
    Document language
    Main Topic
    Lending
    Document Number
    161219389
    Document Focus
    Environmental Information
    Project Number
    20220504
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now
    Environmental and Social Completion Sheet (ESCS) - NOVOZYMES INNOVATIVE BIOTECHNOLOGY SOLUTIONS
    Publication Date
    11 Oct 2025
    Document language
    Main Topic
    Lending
    Document Number
    249647387
    Document Focus
    Environmental Information
    Project Number
    20220504
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

    Related publications